Craig Hallum downgraded shares of AngioDynamics (NASDAQ:ANGO) from a buy rating to a hold rating in a research report released on Friday, MarketBeat.com reports.
A number of other brokerages have also recently commented on ANGO. KeyCorp reaffirmed a hold rating on shares of AngioDynamics in a research note on Friday, September 29th. Zacks Investment Research raised shares of AngioDynamics from a hold rating to a buy rating and set a $19.00 price objective on the stock in a research note on Tuesday, October 3rd. TheStreet cut shares of AngioDynamics from a b- rating to a c rating in a research note on Tuesday, January 2nd. Finally, Canaccord Genuity reaffirmed a hold rating and set a $17.00 price objective on shares of AngioDynamics in a research note on Sunday, October 8th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company. The company has a consensus rating of Hold and an average price target of $18.40.
AngioDynamics (NASDAQ:ANGO) traded up $0.54 during trading hours on Friday, reaching $16.65. 440,700 shares of the company’s stock were exchanged, compared to its average volume of 454,220. The company has a market cap of $611.32, a price-to-earnings ratio of -61.67, a P/E/G ratio of 1.57 and a beta of 1.04. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.65 and a current ratio of 2.56. AngioDynamics has a 1-year low of $14.80 and a 1-year high of $18.85.
AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Thursday, January 4th. The medical instruments supplier reported $0.16 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.16. The business had revenue of $86.70 million during the quarter, compared to analyst estimates of $88.15 million. AngioDynamics had a negative net margin of 2.27% and a positive return on equity of 4.63%. AngioDynamics’s revenue was down 2.6% compared to the same quarter last year. During the same period last year, the business earned $0.19 EPS. sell-side analysts anticipate that AngioDynamics will post 0.68 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. California Public Employees Retirement System grew its stake in shares of AngioDynamics by 6.7% during the 3rd quarter. California Public Employees Retirement System now owns 196,202 shares of the medical instruments supplier’s stock worth $3,353,000 after purchasing an additional 12,302 shares during the period. Highbridge Capital Management LLC lifted its position in shares of AngioDynamics by 21.4% during the 3rd quarter. Highbridge Capital Management LLC now owns 25,304 shares of the medical instruments supplier’s stock valued at $432,000 after buying an additional 4,461 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of AngioDynamics by 49.4% during the 3rd quarter. Janus Henderson Group PLC now owns 1,439,873 shares of the medical instruments supplier’s stock valued at $24,607,000 after buying an additional 476,327 shares in the last quarter. Royce & Associates LP lifted its position in shares of AngioDynamics by 2.9% during the 3rd quarter. Royce & Associates LP now owns 965,157 shares of the medical instruments supplier’s stock valued at $16,495,000 after buying an additional 27,009 shares in the last quarter. Finally, OxFORD Asset Management LLP lifted its position in shares of AngioDynamics by 93.7% during the 3rd quarter. OxFORD Asset Management LLP now owns 168,308 shares of the medical instruments supplier’s stock valued at $2,742,000 after buying an additional 81,432 shares in the last quarter. 95.23% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/09/craig-hallum-downgrades-angiodynamics-ango-to-hold.html.
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.